Skip to main content

Table 1 Demographic, parasitological and symptomatological parameters of the study population

From: On the cytokine/chemokine network during Plasmodium vivax malaria: new insights to understand the disease

Parameters

Value for group

Control

(n = 15)

Endemic Control

(n = 10)

P. vivax

(n = 75)

P. vivax-treated

(n = 10)

Age [median(range)]

27 (19–35)

38 (21–49)

37 (20–80)

42 (21–50)

Gender [n(%)]

 Male

10 (66.7)

6 (60.0)

57 (76.0)

6 (60.0)

 Female

5 (33.3)

4 (40.0)

18 (24.0)

4 (40.0)

Parasitaemia (parasites/mm3), [n = (%)]

 ≤500

34 (45.3)

 501–10,000

26 (34.7)

 10,001–100,000

8 (10.7)

 Without information

7 (9.3)

Nº of previous malaria episodes [n(%)]

 First malaria

3 (30.0)

10 (13.3)

1 (10.0)

 ≤5

2 (20.0)

24 (32)

2 (20.0)

 >5

5 (50.0)

33 (44.0)

6 (60.0)

 Without information

 

0 (0.0)

8 (10.7)

1 (10.0)

Symptoms [n(%)]

 Fever

66 (97.1)

 Headache

66 (97.1)

 Myalgia

61 (89.7)

 Chills

60 (88.2)

 Sweating

51 (75.0)

 Arthralgia

49 (72.1)

 Nausea

36 (52.9)

 Vomiting

20 (29.4)

  1. The parasitaemia and symptoms in the P. vivax-treated group refers to acute phase. The n for symptoms were: P. vivax group (n = 68) and P. vivax-treated group (n = 8)